Shelley Margetson

Stepping into the role of a Chief Executive Officer (CEO) for the first time can be a daunting prospect. In the biotech industry, the journey is marked by a unique set of hurdles, from scientific complexities, to regulatory intricacies, finance, HR, and interactions with a wide range of stakeholders. In this dynamic landscape, the role of the Chair of the Board of Directors becomes pivotal. The Chair is well-positioned to empower and support first-time CEOs, but good synergy between the duo is paramount for success.
Many argue that young companies have little need for a Chief Financial Officer (CFO). They would say that CFOs are unnecessary and costly add-ons early on when a business’ financial needs can be satisfied through outsourcing or by a more junior member of staff. However a CFO brings a deeper and more strategic financial perspective which can help a company outgrow the competition. So, is delaying CFO recruitment a sensible budgetary decision or an expensive mistake?